Patterns of drug treatment of schizophrenic patients in Estonia, Spain and Sweden.

Ra, Kiivet; LLerena, Adrián; Ml, Dahl; Rootslane, L.; Vega, Javier Sánchez; Eklundh, Thomas; Sjöqvist, Folke

doi:10.1111/j.1365-2125.1995.tb05791.x

Cited by 53 publications

(33 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Such studies are rare, although there have been some comparisons of treatments for hospitalized schizophrenia patients between culturally dissimiler countries (Dollfus et al 1996 ;Kiivet et al 1995). Studies of schizophrenia patients in Asia are supported by widespread acceptance of DSM-IV (APA, 1994) and ICD-10 (WHO, 1992) as international standards for the diagnosis of psychotic disorders.…”

Section: Study Design and Participantsmentioning

confidence: 99%

Adjunctive mood stabilizer treatment for hospitalized schizophrenia patients: Asia psychotropic prescription study (2001–2008)

Sim

Yong

Chan

et al. 2011

Int. J. Neuropsychopharm.

View full text Add to dashboard Cite

Recent studies indicate relatively high international rates of adjunctive psychotropic medication, including mood stabilizers, for patients with schizophrenia. Since such treatments are little studied in Asia, we examined the frequency of mood-stabilizer use and its clinical correlates among hospitalized Asian patients diagnosed with schizophrenia in 2001-2008. We evaluated usage rates of mood stabilizers with antipsychotic drugs, and associated factors, for in-patients diagnosed with DSM-IV schizophrenia in 2001, 2004 and 2008 in nine Asian regions: China, Hong Kong, India, Korea, Japan, Malaysia, Taiwan, Thailand, and Singapore. Overall, mood stabilizers were given to 20.4% (n=1377/6761) of hospitalized schizophrenia patients, with increased usage over time. Mood-stabilizer use was significantly and independently associated in multivariate logistic modeling with: aggressive behaviour, disorganized speech, year sampled (2008 vs. earlier), multiple hospitalizations, less negative symptoms, younger age, with regional variation (Japan, Hong Kong, Singapore>Taiwan or China). Co-prescription of adjunctive mood stabilizers with antipsychotics for hospitalized Asian schizophrenia patients increased over the past decade, and was associated with specific clinical characteristics. This practice parallels findings in other countries and illustrates ongoing tension between evidence-based practice vs. individualized, empirical treatment of psychotic disorders.

show abstract

Section: Study Design and Participantsmentioning

confidence: 99%

Adjunctive mood stabilizer treatment for hospitalized schizophrenia patients: Asia psychotropic prescription study (2001–2008)

Sim

Yong

Chan

et al. 2011

Int. J. Neuropsychopharm.

View full text Add to dashboard Cite

show abstract

“…Previous reports had also compared the prescription patterns of inpatients with schizophrenia among psychiatric units in countries with different socio-cultural backgrounds and psychiatric traditions as well as patients of different ethnicities [10,13]. The rationale for the collection of such international data is supported by the current widespread acceptance of the DSM-IV [14] and ICD-10 [15] which had led to a greater consistency in the diagnosis of schizophrenia.…”

Section: Design and Participantsmentioning

confidence: 99%

“…Antipsychotic polypharmacy is associated with more frequent use of adjunctive medications such as anticholinergic drugs [8], higher daily dosing [9], higher rate of adverse effects and underutilization of atypical antipsychotic medications [3,4]. There has been a constant call for more rational psychopharmacotherapy [10,11] in the management of patients with schizophrenia, with the purpose of optimizing the treatment without compromising on the side-effect burden as well as its impact on the patients' quality of life.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Antipsychotic polypharmacy in patients with schizophrenia: a multicentre comparative study in East Asia

Sim

Fujii

et al. 2004

Brit J Clinical Pharma

132

107

View full text Add to dashboard Cite

AimsPrevious studies of the prescription patterns of psychotropic medications in patients with schizophrenia have highlighted a high rate of antipsychotic polypharmacy, but data in Asia are sparse. This study seeks to examine the prevalence of antipsychotic polypharmacy in patients with schizophrenia and compare the differences between patients receiving one vs. those receiving more than one antipsychotic. MethodsAntipsychotic prescription for a sample of 2399 patients with schizophrenia from six countries and territories was evaluated. Daily doses of antipsychotic medications were converted to standard chlorpromazine equivalents (CPZ). ResultsAntipsychotic polypharmacy was found in 45.7% ( n = 1097) of the patients with wide intercountry variations. Polypharmacy was associated with male gender [odds ratio (OR) 1.24, 95% confidence interval (CI) 1.06, 1.46, P < 0.01], advanced age ( t = -7.81, d.f. = 2396, P < 0.001), psychiatric hospital setting (OR 1.34, 95% CI 1.11, 1.62) as well as higher daily CPZeq doses (411.47 vs. 983.10 CPZeq day -1 , z = -25.94, P < 0.001), anticholinergic use (OR 3.17, 95% CI 2.65, 3.79, P < 0.001) and less use of an atypical antipsychotic drug (OR 0.83, 95% CI 0.71, 0.98, P < 0.05). On multivariate analysis, country, age and duration of illness were significantly associated with antipsychotic polypharmacy. ConclusionThis study highlighted the wide intercountry variations of antipsychotic polypharmacy which are likely to be influenced by a complex combination of clinical, setting, cultural and personal practice factors, requiring more research.

show abstract

“…T Antipsychotic polypharmacy (AP) for the treatment of psychosis is a more widespread therapeutic recourse in clinical practice [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18] than might be expected, despite the paucity of data to support it [19] and the consensus statements considering monotherapy as the standard treatment for schizophrenia [20][21][22][23][24]. In a study conducted in japan [18], 90% of patients with schizophrenia were being treated with AP, consisting mainly of first-generation antipsychotic drugs, one with high potency and the other a low potency agent.…”

Section: Introductionmentioning

confidence: 99%

Augmentation Treatment with Amisulpride in Schizophrenic Patients Partially Responsive to Olanzapine

Molina¹,

Toledo-Romero²,

López-Rodríguez³

et al. 2011

Pharmacopsychiatry

View full text Add to dashboard Cite

show abstract

Patterns of drug treatment of schizophrenic patients in Estonia, Spain and Sweden.

Cited by 53 publications

References 25 publications

Adjunctive mood stabilizer treatment for hospitalized schizophrenia patients: Asia psychotropic prescription study (2001–2008)

Adjunctive mood stabilizer treatment for hospitalized schizophrenia patients: Asia psychotropic prescription study (2001–2008)

Antipsychotic polypharmacy in patients with schizophrenia: a multicentre comparative study in East Asia

Augmentation Treatment with Amisulpride in Schizophrenic Patients Partially Responsive to Olanzapine

Contact Info

Product

Resources

About